Senna
Brand names: Senokot, Manevac
Senna is a stimulant laxative for the short-term treatment of constipation.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKDirections take preferably at bedtime or as directed by a doctor adults and children 12 years of age or older - starting dosage: 2 tablets once a day, maximum dosage: 4 tablets twice a day children 6 to under 12 years - starting dosage: 1 tablet once a day, maximum dosage: 2 tablets twice a day children 2 to under 6 years - starting dosage: 1/2 tablet once a day, maximum dosage: 1 tablet twice a day children under 2 years - starting dosage: ask a doctor, maximum dosage: ask a doctor
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2023-10-21. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Clinical monograph
How it works
Its anthraquinone components stimulate colonic motility and secretion, usually producing a bowel movement within about 8-12 hours.
Prescribing in practice
- Avoid in intestinal obstruction.
- Use it short-term — prolonged use can lead to dependence and electrolyte disturbance.
- Address underlying causes, fluid and fibre intake.
Monitoring
Review bowel habit; no routine monitoring.
Counselling the patient
- It usually works overnight.
- Drink plenty of fluids.
- It is not for regular long-term daily use without advice.
Evidence & guidelines
A first-line stimulant laxative for constipation per NICE CKS guidance.
Reference: NICE NG31 Palliative Care — Constipation; SPC Senokot; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021